![Mark W. Grinstaff](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
John Schwartz | M | - |
AcuityBio Corp.
![]() AcuityBio Corp. Pharmaceuticals: MajorHealth Technology AcuityBio Corp. engages in the commercialization of novel polymer drug-delivery technologies to treat various types of early stage, soft tissue cancers. It offers ABC103 solution. The company was founded by Mark Grinstaff, Alain Hanover, Jesse Wolinsky, and John Schwartz in 2009 and is headquartered in Newtonvillen, MA. | 15 years |
Daniel J. Kenan | M | - |
Affinergy LLC
![]() Affinergy LLC BiotechnologyHealth Technology Affinergy LLC develops site-specific biological systems using biofriendly linkers that selectively adhere to proteins, drugs, cells, and biomaterial surfaces. The firm focuses on developing coatings and medical devices for the orthopedic and cardiovascular markets. It constructs bifunctional peptide linkers that selectively immobilize proteins, cells, and therapeutics onto biomaterial surfaces. The firm offers its products for orthopedics, cardiovascular, and tissue engineering; and drug delivery and stem cells markets. The company was founded by Daniel J. Kenan, Jonathan Gindes, and Mark W. Grinstaff in 2002 and is headquartered in Durham, NC. | 22 years |
Jon Westling | M | 82 |
Boston University
| - |
Karen English | F | - |
AcuityBio Corp.
![]() AcuityBio Corp. Pharmaceuticals: MajorHealth Technology AcuityBio Corp. engages in the commercialization of novel polymer drug-delivery technologies to treat various types of early stage, soft tissue cancers. It offers ABC103 solution. The company was founded by Mark Grinstaff, Alain Hanover, Jesse Wolinsky, and John Schwartz in 2009 and is headquartered in Newtonvillen, MA. | 20 years |
Cornelius K. Hurley | M | 78 |
Boston University
| - |
George A. Russell | M | - |
Boston University
| - |
Sheldon L. Glashow | M | 91 |
Boston University
| 24 years |
James L Kirkland | M | - |
Boston University
| - |
Michael A. Eruzione | M | 69 |
Boston University
| 29 years |
Kamakshi Sivaramakrishnan | M | 48 |
Boston University
| - |
Nina Tassler | F | - |
Boston University
| - |
Rick Swanborg | M | - |
Boston University
| - |
Clarissa C. Hunnewell | F | - |
Boston University
| 13 years |
Douglass Karp | M | - |
Boston University
| - |
Thomas A. Einhorn | M | - |
Boston University
| - |
Paul Alexander | M | 63 |
Boston University
| - |
Max Versace | M | - |
Boston University
| - |
Jeff Terrey | M | - |
Boston University
| - |
Pritiraj Mohanty | M | - |
Boston University
| - |
Paul F. Pilch | M | - |
Boston University
| - |
Stefan T. Midford | M | - |
Boston University
| - |
William DeJong | M | - |
Boston University
| - |
Andrew Weiss | M | - |
Boston University
| - |
Lee Goldstein | M | - |
Boston University
| - |
Angelo Guadagno | M | - |
Boston University
| - |
Martin J Howard | M | - |
Boston University
| - |
Arturo Jose Vegas | M | - |
Boston University
| - |
Antoinette Leatherberry | F | 62 |
Boston University
| - |
Emily Lake | F | - |
Boston University
| - |
Julia Binda | F | - |
Boston University
| - |
Victor Olakojo | M | - |
Boston University
| - |
Liam McCartney | M | - |
Boston University
| - |
Samantha Fifield | F | - |
Boston University
| - |
Isabella Luizzi | F | - |
Boston University
| - |
Tom Cassaro | M | - |
Boston University
| - |
Griffin Monahan | M | - |
Boston University
| - |
Derrick Newton | M | - |
Boston University
| - |
Daniel Terner | M | - |
Boston University
| - |
Jonathan Aleshire | M | - |
Boston University
| - |
Jerome S. Brody | M | - |
Boston University
| - |
Matthew Gallery | M | - |
Boston University
| - |
Randy Jose | M | - |
Boston University
| - |
Brian Poznanski | M | - |
Boston University
| - |
Darius Haghighat | M | - |
Boston University
| - |
Alicia Borinsky | F | - |
Boston University
| - |
Bill Keogh | M | - |
AcuityBio Corp.
![]() AcuityBio Corp. Pharmaceuticals: MajorHealth Technology AcuityBio Corp. engages in the commercialization of novel polymer drug-delivery technologies to treat various types of early stage, soft tissue cancers. It offers ABC103 solution. The company was founded by Mark Grinstaff, Alain Hanover, Jesse Wolinsky, and John Schwartz in 2009 and is headquartered in Newtonvillen, MA. | 3 years |
John F. Smith | M | 86 |
Boston University
| - |
Michael DiFabio | M | - |
Boston University
| - |
Peter Lui | M | - |
AcuityBio Corp.
![]() AcuityBio Corp. Pharmaceuticals: MajorHealth Technology AcuityBio Corp. engages in the commercialization of novel polymer drug-delivery technologies to treat various types of early stage, soft tissue cancers. It offers ABC103 solution. The company was founded by Mark Grinstaff, Alain Hanover, Jesse Wolinsky, and John Schwartz in 2009 and is headquartered in Newtonvillen, MA. | - |
James Tracy | M | - |
Boston University
| - |
Avrum Spira | M | - |
Boston University
| - |
Douglas Faller | M | - |
Boston University
| - |
Maria N. Potapov | F | - |
Boston University
| - |
Lance Piccolo | M | 83 |
Boston University
| - |
Ian Mashiter | M | - |
Boston University
| - |
Paul Edwards | M | 70 |
Boston University
| - |
Kenneth Lin | M | 48 |
Boston University
| 3 years |
Daniel T. Steele | M | - |
Boston University
| 9 years |
Robert A. Brown | M | 72 |
Boston University
| 19 years |
Kenneth G. Condon | M | 76 |
Boston University
| 49 years |
Edwin J. Delattre | M | 82 |
Boston University
| 23 years |
Fred K. Foulkes | M | 82 |
Boston University
| 44 years |
Ira Cohen | M | 73 |
Boston University
| 12 years |
Kenneth Freeman | M | 73 |
Boston University
| 4 years |
Prem Kishan Dass Gupta | M | 66 |
Boston University
| - |
Edward Boches | M | - |
Boston University
| - |
Michael D. Fricklas | M | 64 |
Boston University
| - |
David D'Alessandro | M | 73 |
Boston University
| - |
Nathaniel Dalton | M | 57 |
Boston University
| 6 years |
Charley Lax | M | - |
Boston University
| - |
Stephen Zide | M | 64 |
Boston University
| 14 years |
Robert McLellan | M | 69 |
Boston University
| 23 years |
David A. Krohn | M | - |
Boston University
| - |
Richard D. Reidy | M | 64 |
Boston University
| - |
Ed D. de Castro | M | 84 |
Boston University
| - |
Burton J. Polansky | M | - |
Boston University
| - |
Peter Russo | M | - |
Boston University
| - |
Jorge Morán Sánchez | M | 59 |
Boston University
| - |
Susan P. Perrine | M | - |
Boston University
| - |
Robert J. Brown | M | 89 |
Boston University
| - |
Maurice R. Ferré | M | 63 |
Boston University
| - |
Gerald Fine | M | 65 |
Boston University
| 12 years |
Marc S. Weinberg | M | - |
Boston University
| - |
Jevin Eagle | M | 57 |
Boston University
| - |
Tom Valle | M | - |
Boston University
| - |
Jill Roosevelt | F | - |
Boston University
| - |
S. D. Shibulal | M | 69 |
Boston University
| - |
Robert Friedman | M | - |
Boston University
| - |
Gail Douglas | F | - |
Boston University
| - |
Eyal S. Ron | M | 69 |
AcuityBio Corp.
![]() AcuityBio Corp. Pharmaceuticals: MajorHealth Technology AcuityBio Corp. engages in the commercialization of novel polymer drug-delivery technologies to treat various types of early stage, soft tissue cancers. It offers ABC103 solution. The company was founded by Mark Grinstaff, Alain Hanover, Jesse Wolinsky, and John Schwartz in 2009 and is headquartered in Newtonvillen, MA. | 15 years |
Theresa A. Nibi | F | - |
Boston University
| 17 years |
Barbara E. Corkey | M | - |
Boston University
| - |
Hugo Shong | M | 68 |
Boston University
| 19 years |
Reed Holden | M | - |
Boston University
| - |
Elliot H. Cole | M | 86 |
Boston University
| - |
James T. Stamas | M | 91 |
Boston University
| 29 years |
Barry S. Zuckerman | M | - |
Boston University
| - |
Stephen R. Karp | M | 83 |
Boston University
| - |
Bettina Briz | F | - |
Boston University
| 13 years |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Jonathan Gindes | M | - |
Affinergy LLC
![]() Affinergy LLC BiotechnologyHealth Technology Affinergy LLC develops site-specific biological systems using biofriendly linkers that selectively adhere to proteins, drugs, cells, and biomaterial surfaces. The firm focuses on developing coatings and medical devices for the orthopedic and cardiovascular markets. It constructs bifunctional peptide linkers that selectively immobilize proteins, cells, and therapeutics onto biomaterial surfaces. The firm offers its products for orthopedics, cardiovascular, and tissue engineering; and drug delivery and stem cells markets. The company was founded by Daniel J. Kenan, Jonathan Gindes, and Mark W. Grinstaff in 2002 and is headquartered in Durham, NC. | 20 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Mark W. Grinstaff
- Personal Network